The Utility of Older Generic Medicines in the Current AAD Practice of Dermatology

Liz Jones, an associate professor at Jefferson in Philadelphia, discusses the utility of the older generic medicines dapsone and colchicine in dermatological practice at the American Academy of Dermatology. Both medications are noted for their anti-inflammatory properties without causing immunosuppression, which is crucial for patients with complex conditions. Jones presents a case of a 69-year-old patient with type 2 mixed cryoglobulinemia who struggled with flares and sought alternatives to immunosuppressive therapy. Dapsone was initiated, showcasing its FDA-approved uses and expanding benefits for various dermatological issues. Jones emphasizes the importance of monitoring for side effects like methemoglobinemia and hemolysis, particularly in populations susceptible to G6PD deficiency. Colchicine, although lacking FDA approval in dermatology, is highlighted for its anti-inflammatory role and similar utility against neutrophilic conditions. The discussion covers both medications regarding dosing, potential adverse effects, necessary monitoring protocols, and advice on lifestyle modifications for patients. As both drugs are cost-effective and provide benefits without immunosuppression, they remain significant options in managing chronic inflammatory dermatological conditions. Jones concludes by acknowledging the need for further research into these medications and their effectiveness in clinical practice.